View on market: Stay Cautious, be with quality business:

Asian markets were weak on Friday even as US shares closed higher on Thursday following strong US economic data and the Federal Reserve’s commitment to continue supporting the economy. China’s purchasing managers surveys signalled expansion in manufacturing and services activity in the world’s second-largest economy, after the U.S. reported growth at a 6.4% annualised pace in the first quarter. The Singapore-traded SGX Nifty, an early indicator of the Nifty 50 Index’s performance in India, was down 1.1 percent at 14762 as of 8:10 a.m

Key Data/ Action, Result and Board meeting to watch

Major economic Data:

  • INR: Infrastructure Output YoY (Mar) on 30th April, 2021
  • INR: Markit Manufacturing PMI (pr) on 3rd May, 2021

Nifty Results: Reliance Industries, IndusInd Bank

Non-Nifty Results: Accelya Solutions India, Ajanta Pharma, Astec Lifesciences, Atul, Can Fin Homes, Indian Hotels Co, Marico, RPG Life Sciences, Shriram City Union Finance, Supreme Petrochem, Trent, Yes Bank

International Markets:

U.S & Europe

Particulars    29th Apr. Chg Chg(%)
Nasdaq 14082.55 31.52 0.22
Dow 34060.36 239.98 0.71
FTSE 6961.48 -2.19 -0.03
CAC 6302.57 -4.41 -0.07
DAX 15154.2 -137.98 -0.9
Dow Fut.* 33,881.00 -71 -0.21

Asian markets:

Particulars    30th Apr. Chg Chg(%)
SGX Nifty 14762.2 -163.50 -1.10
Nikkei 28902.19 -151.78 -0.52
Straits Times 3235.35 13.77 0.43
Hang Seng 28910.06 -393.2 -1.34
Shanghai 3457.3 -17.6 -0.51

ADR Watch:

Particulars       29th Apr. Chg Chg(%)
Dr Reddy 68.96 0.96 1.41
HDFC Bank 73.13 -1.09 -1.47
ICICI Bank 16.77 0 0
Infosys 18.46 0.23 1.26
Tata Motor 20.1 -0.33 -1.62
Wipro 7.31 0.1 1.39

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR       74.04     -0.42
Brent 67.78        -0.42
Gold 1,766.90     -0.08
Silver 26     -0.20


Particulars   29th Apr.       28th Apr.
FIIs 809.37       766.02
DIIs    -942.35     436.20


Titan Q4FY21 (Consolidated, YoY)

Revenue up 59% at Rs 7494 crore Vs Rs 4711 crore (Bloomberg Estimate: Rs 7,516.8 crore) Net profit up 66% at Rs 568 crore Vs Rs 343 crore (Bloomberg Estimate: Rs 549 crore) EBITDA up 33% at Rs 817 crore Vs Rs 612 crore (Bloomberg Estimate: Rs 841 crore) Margin at 10.9% Vs 13% (Bloomberg Estimate: 11.2%) Recommended a dividend of Rs 4 per share

Indiamart Intermesh Q4FY21 (Consolidated, YoY)

Revenue up 6% at Rs 179.7 crore Vs Rs 170.1crore Net Profit up 26% to Rs 55.7 crore Vs Rs 44.3 crore Ebitda up 63% at Rs 85.4 crore vs Rs 52.3 crore Ebitda margins at 47.5% vs 30.7% Recommended a final dividend of Rs 15 per share for FY21

Ambuja Cements Q1CY21 (Consolidated, YoY)

Revenue up 23% at Rs 7,714.81 crore Vs Rs 6,249.66 crore Net Profit up 71% at Rs 947.21 crore Vs Rs 554.25 crore Ebitda up 54% at Rs 1,838.49 crore Vs Rs 1,191.33 crore Ebitda margins at 23.8% Vs 19.1%

News Update:

Reliance Industries:

The street expects Reliance overall revenue growth in the fourth quarter of FY21 to be up about 23 percent on a quarter on quarter (QoQ) basis. This topline growth will be driven by the oil to chemical (O2C) business. The other segmental performance contribution to the topline – retail will be about mid-single-digit QoQ growth while Jio will report a decline in their revenues quarter on quarter. The way the Singapore gross refining margins (GRMs) have moved, the expectation is that refining will be the driver of growth. For Jio, the key to track will be the subscriber addition because it has been muted for the last couple of quarters and this quarter the interconnect usage charge was removed. So that will have a direct flow on the company’s performance for Jio.

Dr. Reddy’s Laboratories:

Has launched Albendazole Tablets, USP–a therapeutic equivalent generic version of Albenza Tablets, 200 mg–in the U.S. market

Ujjivan Financial Services:

A special resolution to appoint Samit Ghosh as CEO of Ujjivan Financial Services Ltd. was defeated as it didn’t get the requisite share of votes. According to details available on the stock exchange, the proposal for appointment Ghosh only received 70.5% votes in favour.

HDFC Bank:

Has appointed Atanu Chakraborty as part-time Chairperson and Additional Independent Director on the board of the bank, subject to the approval of the shareholders, for a period of three years, with effect from May 5.


Has partnered with Citrix and Hewlett Packard Enterprise to accelerate remote working solutions and bring modernisation into workspaces.

Manappuram Finance:

The company is considering various options for raising funds through borrowings including by the way of issuance of debt securities in onshore and offshore securities market by public issue, on a private placement basis or through issuing commercial papers. The Board of Directors may consider and approve issuances of debt securities in May.

Offerings: PowerGrid InvIT IPO gets 10% demand on first day of the sale.

L&T Finance:

The shadow lender reported a fall of 30.89% in consolidated net profit at ₹267 crore for the quarter ending 31 March. The NBFC’s total income during the quarter advanced to ₹3,587.18 crore from ₹3427.22 crore in the year-ago quarter. The rural finance book grew by 9% year-on-year.

Source: Moneycontrol, Livemint, Business Standard, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit Disclosures Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting , or e-mailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person. Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company in the analyst’s area of coverage. Country Specific Disclosures India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking
or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.